Robert E. Gerberich

Chief Commercial Officer

Robert “Bob” Gerberich, Chief Commercial Officer, is a results-driven global business leader with over 30 years of experience in the surgical and medical device segments of the life sciences market. As a senior sales and marketing executive, he has an exceptional track record of success building new markets and driving rapid commercial growth from product introduction through broad scale adoption. Bob joined Magnolia Medical Technologies as Chief Commercial Officer in April 2017. He is responsible for leading all commercial and customer-facing functions of the company including sales, clinical, marketing and customer service & support.

Most recently, Bob served as Vice President of Sales and Marketing and Vice President of Sales at Invuity, Inc. (NASDAQ: IVTY) acquired by Stryker (NYSE: SYK). Under his direct commercial leadership, Invuity transformed into a rapid growth direct sales-driven advanced surgical photonics company leading the advancement of open minimal access surgery. Bob led the company from a $3 million to $50 million revenue run rate, delivering 17 consecutive quarters of quarter-over-quarter sales growth. He also drove the creation, launch and implementation of strategic marketing and partnership programs. The commercial impact of these programs supported the successful Initial Public Offering (IPO) of the company in June of 2015.

Prior to Invuity, Bob served as President of UltraShape North America and Head of Global Sales for UltraShape Ltd acquired by Syneron Medical Ltd. (NASDAQ: ELOS), where he established the North American subsidiary for UltraShape and launched the first non-surgical focused ultrasound body sculpting technology in the world.

Before UltraShape, Bob was Vice President of Sales and Marketing and Vice President of Sales for Thermage, Inc. now Solta Medical, a division of Valeant Pharmaceuticals (NYSE:VRX), where he led the successful platform launch of a proprietary radio-frequency technology, creating a new market for non-invasive tissue tightening. He built a direct sales organization from the ground up and led the company from $0 to a $50 million revenue run rate.

Earlier in his career, Bob led dynamic and fast-growing sales organizations at several other medical device companies within the hospital markets including INAMED Aesthetics, acquired by Allergan (NYSE: AGN), LySonix Inc., acquired by Mentor Worldwide, division of J&J (NYSE: JNJ), Leibinger L.P. acquired by Stryker (NYSE: SYK), and Davol Inc. Blood Mgmt. Group subsidiary of CR Bard (NYSE: BCR). Bob holds a BS. in Marketing from Illinois State University.